18th août 2022
Actualités
Retrouvez tous nos derniers communiqués de presse. Restez informé des dernières actualités et des événements auxquels participe Curium.
27th juin 2022
Curium Announces The Submission Of Its Marketing Authorization Application For [18F]-DCFPyL To The European Medicines Agency
12th mai 2022
Curium Confirms No Supply Challenges of 177Lu-PSMA-I&T for ECLIPSE Trial
3rd mai 2022
Curium’s Phase 3 ECLIPSE Trial Starts Enrolling Patients
19th avril 2022
Curium Announces Significant Increase in Detectnet™ (copper Cu 64 dotatate injection) Production Capacity
5th avril 2022
Curium Announces FDA Approval of a Generic Version of DaTscan™ (Ioflupane I 123 Injection) in the U.S.
25th janvier 2022
Curium to become major player in the supply on non carrier added Lu-177
15th décembre 2021
Curium is pleased to announce that Sakir Mutevelic MD, MSc has joined as global Chief Medical Officer
27th octobre 2021
Curium Initiates ECLIPSE, a Phase 3 Clinical Trial For Its Investigational Lu 177 PSMA I&T
24th août 2021
Curium Announces Submission of an Investigational New Drug (IND) Application for Cu-64 PSMA I&T
1st juin 2021
Curium Acquires Austrian Radiopharmaceuticals Company IASON
5th mai 2021
RadioMedix & Curium Announce Detectnet™ (copper Cu 64 dotatate injection) Inclusion on NCCN Guidelines®
4th mai 2021
Curium Announces Filing of a Generic Version of DaTscan™ (Ioflupane I 123 Injection) in the U.S.
28th avril 2021
Curium to Expand Noblesville Facility’s Workforce
23rd mars 2021
RadioMedix & Curium Announce Simplified Coding for Detectnet™ (copper Cu 64 dotatate injection)
17th mars 2021
A statement on the use of Xenon Xe 133 Gas during the COVID-19 pandemic
2nd mars 2021
Eckert & Ziegler’s GalliaPharm® distributed by Curium in France
26th janvier 2021
RadioMedix & Curium Announce Permanent HCPCS Code for Detectnet™ (copper Cu 64 dotatate injection)
9th décembre 2020
RadioMedix & Curium Announce CMS Transitional Pass-Through Status for Detectnet™ (copper Cu 64 dotatate injection)
8th septembre 2020